Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-090871
Filing Date
2024-08-05
Accepted
2024-08-05 16:41:18
Documents
59
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q etnb-20240630.htm   iXBRL 10-Q 1774359
2 EX-10.1 etnb-ex10_1.htm EX-10.1 179069
3 EX-31.1 etnb-ex31_1.htm EX-31.1 14746
4 EX-31.2 etnb-ex31_2.htm EX-31.2 14758
5 EX-32 etnb-ex32.htm EX-32 15015
  Complete submission text file 0000950170-24-090871.txt   7836369

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT etnb-20240630.xsd EX-101.SCH 1256674
62 EXTRACTED XBRL INSTANCE DOCUMENT etnb-20240630_htm.xml XML 1252533
Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39122 | Film No.: 241175457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)